2 May 2015
Matt Bomer and Max Greenfield at the Taste For A Cure 2015 event. Image: Getty Images
The 20th Annual Jonsson Cancer Center Foundation’s ‘Taste For A Cure’ was held Friday, May 1 at the Beverly Wilshire Hotel. The evening honored David Madden, President of Entertainment at Fox Broadcasting Company with the Gil Nickel Humanitarian Award.
In attendance was Matt Bomer along with many other distinguished guests, with Bomer presenting the Gil Nickel Humanitarian Award to David Madden. The annual fundraiser has raised approximately $10Mil over the past 19 years for cancer research at UCLA.
Chef Piero Selvaggio (Valentino), Curating Chef for the evening, along with his team of participating chefs which included Vittorio Lucariello (Beverly Wilshire Hotel), Steve Samson (Sotto), Salvatore Marino (Il Grano), Giacomino Drago (Il Pastio) served up delectable Italian delights along with pregious Italian wines.
The evening included a live auction (as well as an online auction) that included exceptional trips, including a Tuscan getaway and an instant Italian wine cellar with wines supplied by distinguished Italian wineries.
Jonsson Comprehensive Cancer Center has established an international reputation for developing new cancer therapies, providing the best in experimental and traditional cancer treatments and expertly guiding and training the next generation of medical research.
As defined by the National Cancer Institute (NCI), the mission of UCLA´s Jonsson Comprehensive Cancer Center(JCCC) is as follows:
NCI-designated Cancer Centers are a major source of discovery of the nature of cancer and of the development of more effective approaches to cancer prevention, diagnosis and therapy. They also deliver medical advances to patients and their families, educate health-care professionals and the public and reach out to underserved populations. They are characterized by: strong organizational capabilities; institutional commitment; trans-disciplinary, cancer-focused science; experienced scientific and administrative leadership and state-of-the-art cancer research and patient care facilities.
CCC has established an international reputation in a number of areas, such as:
- Developing new cancer therapies
- Providing the best in experimental and traditional treatments
- Expertly guiding and training the next generation of medical researchers
Numerous successful targeted therapies were developed based on basic science done in UCLA laboratories and later clinical research with UCLA patients. A few of the more well-known therapies include:
- Herceptin, a targeted breast cancer drug and the first approved treatment that attacks cancer at its genetic roots
- Gleevec, a once-a-day pill that targets a common form of adult leukemia called chronic myelogenous leukemia, or CML
- Sprycel, also a pill that targets CML
- Tarceva, a targeted lung cancer drug
- Avastin, a targeted drug for colorectal cancer and lung cancer
Read more about JCCC’s firsts.
